Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma

Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled "Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021," was published in the International Journal of Cancer and highlights the potential benefits of early use of liver-directed therapies, including chemosaturation (also known as percutaneous hepatic perfusion or PHP), in achieving long-term survival for patients with metastatic uveal melanoma (mUM) and liver metastases. The analysis underscores PHP's advantages in disease control compared to other therapies, supporting its early integration potentially ahead of systemic options or in combination with systemic therapies.

The retrospective analysis evaluated 167 patients with mUM who developed liver metastases between 2005 and 2021, focusing on the 33 long-term survivors (20% of the cohort) who lived three or more years following the initial diagnosis of liver metastases. Key findings include:

• The majority of long-term survivors (82%) received liver-directed therapy as their first-line treatment in the metastatic setting
• 90% of long-term survivors received at least one liver-directed therapy at any time, with 85% also receiving immune checkpoint inhibitors (ICI) at some point
• In patients who received first line liver-specific therapy, response evaluation showed a disease control rate of 93% (complete response, partial response, or stable disease) versus 63% for patients who received first line systemic therapy
• 52% percent of long-term survivors received PHP at any time point, achieving a median overall survival of 37.35 months and progression-free survival of 10.28 months